ClinicalTrials.gg
TerminatedNCT03429556Updated Aug 5, 2019Results posted

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

A Phase 2 interventional study of Botulinum Neurotoxin Serotype E and Placebo in Abdominoplasty, sponsored by Allergan. Terminated at 2 sites in United States. Open to participants aged 23 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-08-05.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Sponsor decision to terminate early

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
23 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Pain by AbbVie — none open to participants now, none under way, none of them phase 3. Pain · AbbVie.

Enrollment
17th of 17
23 · median 155
Started
2018
the only one that year
Phase 2
14 of 19
none open now
Registered
19th of 19
by date

Among the 19 studies in Pain by AbbVie, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2018, is one of 14 in phase 2, and was the 19th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 19 studies in Pain by AbbVie is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 23 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Pain by AbbVie as a file.
02

Study summary

To determine the safety and efficacy of single intra-operative treatment of Botulinum Neurotoxin Serotype E (EB-001) intramuscular (IM) injections into the Rectus Abdominus (RA) in participants undergoing abdominoplasty.

03

Conditions studied

  • Abdominoplasty

Browse trials for

Keywords

  • pain, neurotoxin
04

Who can participate

Ages eligible
23 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women 23 to 55 years of age, inclusive
  2. Scheduled to undergo elective abdominoplasty surgery with full length plication from xyphoid to pubis, and removal of skin/fat flap under general anesthesia (endotracheal or otherwise) without liposuction
  3. (ASA) Physical Class 1-2.

Exclusion criteria

Exclusion Criteria:

  1. History of prior major abdominal surgery as judged by the investigator
  2. Pre-existing lung disease that could impact participant safety in the opinion of the investigator
  3. Pre-existing disorders of the neuromuscular junction (myasthenia gravis, Eaton- Lambert syndrome, or amyotrophic lateral Sclerosis)
  4. At high risk of deep vein thrombosis as judged by the investigators determined by a Caprini score of 3 or higher
  5. Slow vital capacity that is below 80% of normal value for respective race, age, height, and gender or below 2.5 Liters (L) of absolute volume
  6. Pulse oximetry below 95%
  7. Body weight less than 50 kg (110 pounds) or a (BMI) of ≥ 32
  8. Reported use of any botulinum toxin within 3 months prior to the date of surgery
  9. Use of long acting opioids within 3 days or any opioid medication within 24 hours prior to surgery
  10. Aminoglycoside intake within 48 hours prior to or during surgery
  11. Participants on anti-depressant or anti-psychotic medications
  12. Reported pain score of 2 or more at screening on the 11-point scale numerical pain rating scale-administered after an activity (NPRS-A) following an activity after and walking approximately 10 feet.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.

    Drug: Placebo

  • Experimental
    Botulinum Neurotoxin Serotype E Dose 1

    Single botulinum neurotoxin serotype E Dose 1 injection into RA muscles during abdominoplasty surgery.

    Biological: Botulinum Neurotoxin Serotype E

  • Experimental
    Botulinum Neurotoxin Serotype E Dose 2

    Single botulinum neurotoxin serotype E Dose 2 injection into RA muscles during abdominoplasty surgery.

    Biological: Botulinum Neurotoxin Serotype E

  • Experimental
    Botulinum Neurotoxin Serotype E Dose 3

    Single botulinum neurotoxin serotype E Dose 3 injection into RA muscles during abdominoplasty surgery.

    Biological: Botulinum Neurotoxin Serotype E

Interventions

  • BiologicalBotulinum toxin type EStudies of Botulinum toxin type EBotulinum toxin type E pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.

    Also known as: EB-001, BoNT/E

  • DrugPlacebo

    Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 12 to 96 hours postsurgery

Secondary outcomes

  1. AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 0 to 96 hours postsurgery

  2. AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 0 to 72 hours postsurgery

  3. AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 0 to 48 hours postsurgery

  4. AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 0 to 24 hours postsurgery

  5. AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)

    The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

    Time frame: Every 2 hours from 12 to 24 hours postsurgery

  6. Participants Overall Assessment of Pain Using the NPRS After Discharge

    The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.

    Time frame: Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26

  7. Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)

    The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately ≥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.

    Time frame: 8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge

  8. Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories

    The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.

    Time frame: Days 5, 8, 15 and 29

  9. Number of Doses of Rescue Medications Used

    Time frame: Up to 96 hours postsurgery

07

Results

Posted Aug 5, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
Started12443
Completed12343
Not completed0100
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryArea Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 12 to 96 hours postsurgery
Reported as:
Mean · hour (hr)*score on a scale
Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)
hour (hr)*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
Area Under the Curve (AUC) of Participant's Assessment of Pain Using the Numerical Pain Rating Scale (NPRS) at Rest Between 12 and 96 Hours Postsurgery (AUC12-96)321.18 ± 217.993209.30 ± NA415.40 ± 124.101372.53 ± 135.799
SecondaryAUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 0 to 96 hours postsurgery
Reported as:
Mean · hr*score on a scale
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery
hr*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 96 Hours Postsurgery403.80 ± 229.152282.50 ± NA506.83 ± 130.598450.97 ± 139.769
SecondaryAUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 0 to 72 hours postsurgery
Reported as:
Mean · hr*score on a scale
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)
hr*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 72 Hours Postsurgery (AUC0-72)338.91 ± 173.785280.50 ± NA416.70 ± 97.464372.47 ± 86.226
SecondaryAUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 0 to 48 hours postsurgery
Reported as:
Mean · hr*score on a scale
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)
hr*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 48 Hours Postsurgery (AUC0-48)253.53 ± 106.862240.80 ± NA283.20 ± 60.450274.47 ± 32.686
SecondaryAUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 0 to 24 hours postsurgery
Reported as:
Mean · hr*score on a scale
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)
hr*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 0 and 24 Hours Postsurgery (AUC0-24)144.49 ± 46.693149.80 ± NA155.53 ± 28.726146.30 ± 21.717
SecondaryAUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)

The participant assessed their current pain using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable. AUC was calculated using the standard trapezoidal rule.

Time frame:
Every 2 hours from 12 to 24 hours postsurgery
Reported as:
Mean · hr*score on a scale
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)
hr*score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
AUC of Participant's Assessment of Pain Using the NPRS at Rest Between 12 and 24 Hours Postsurgery (AUC12-24)61.91 ± 32.21076.60 ± NA64.10 ± 22.82567.83 ± 18.827
SecondaryParticipants Overall Assessment of Pain Using the NPRS After Discharge

The participant assessed their pain after discharge using the 11-point NPRS where: 0=no pain to 10=worst pain imaginable.

Time frame:
Days 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24 and 26
Reported as:
Mean · score on a scale
Participants Overall Assessment of Pain Using the NPRS After Discharge
score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
Day 62.3 ± 1.660.0 ± NA6.0 ± 1.832.3 ± 2.08
Day 72.3 ± 2.780.0 ± NA3.8 ± 0.503.0 ± 3.00
Day 81.8 ± 1.790.0 ± NA3.5 ± 1.733.0 ± 3.00
Day 92.1 ± 2.620.0 ± NA5.3 ± 1.501.5 ± 2.12
Day 101.8 ± 1.920.0 ± NA4.0 ± 0.821.5 ± 2.12
Day 111.8 ± 2.280.0 ± NA3.3 ± 1.501.5 ± 2.12
Day 121.7 ± 1.870.0 ± NA2.5 ± 1.291.5 ± 2.12
Day 131.7 ± 1.730.0 ± NA3.0 ± 0.002.0 ± 2.83
Day 141.7 ± 1.940.0 ± NA2.3 ± 1.712.0 ± 2.83
Day 161.9 ± 2.470.0 ± NA2.0 ± 0.821.5 ± 2.12
Day 181.6 ± 2.260.0 ± NA1.8 ± 0.961.5 ± 2.12
Day 201.6 ± 2.200.0 ± NA1.8 ± 0.961.5 ± 2.12
Day 221.1 ± 1.730.0 ± NA1.0 ± 1.411.5 ± 2.12
Day 241.5 ± 2.450.0 ± NA1.0 ± 1.412.0 ± 2.83
Day 261.3 ± 1.980.0 ± NA1.0 ± 1.411.5 ± 2.12
SecondaryParticipant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)

The participant assessed their pain using the 11-point NPRS-A, after sitting up in the bed unassisted at an angle of approximately ≥ 45 degrees, swinging legs out, putting feet down, standing up, and walking approximately 10 feet, where: 0=no pain to 10=worst pain imaginable.

Time frame:
8, 16, 24, 30, 36, 42, 48, 54, 60, 66, 72.78.84, and 96 hours after surgery; Days 8, 15 and 29 after discharge
Reported as:
Mean · score on a scale
Participant's Overall Assessment of Pain Using the NPRS-Activity (NPRS-A)
score on a scalePlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
8 hours after surgery6.9 ± 2.745.0 ± NA6.0 ± 2.456.3 ± 0.58
16 hours after surgery8.7 ± 1.534.0 ± NA—7.0 ± NA
24 hours after surgery6.6 ± 2.405.0 ± NA7.5 ± 1.296.3 ± 0.58
30 hours after surgery6.5 ± 2.455.0 ± NA7.0 ± 2.165.0 ± 2.00
36 hours after surgery6.3 ± 1.894.0 ± NA6.5 ± 1.296.3 ± 0.58
42 hours after surgery5.8 ± 1.47———
48 hours after surgery4.3 ± 1.503.0 ± NA5.3 ± 1.713.7 ± 1.53
54 hours after surgery4.8 ± 1.202.0 ± NA6.3 ± 3.104.0 ± 2.00
60 hours after surgery6.3 ± 2.753.0 ± NA6.0 ± 1.413.3 ± 2.52
66 hours after surgery4.7 ± 3.20———
72 hours after surgery3.7 ± 2.450.0 ± NA4.0 ± 2.713.0 ± 1.73
78 hours after surgery3.6 ± 2.620.0 ± NA4.5 ± 2.083.3 ± 2.08
84 hours after surgery4.5 ± 3.321.0 ± NA5.0 ± 1.153.0 ± 2.65
96 hours after surgery2.4 ± 1.810.0 ± NA3.5 ± 1.293.3 ± 3.06
Day 8 after discharge2.1 ± 2.201.0 ± NA4.8 ± 1.713.3 ± 3.06
Day 15 after discharge1.6 ± 1.770.0 ± NA3.8 ± 2.992.7 ± 2.31
Day 29 after discharge1.5 ± 1.97—0.5 ± 0.580.0 ± NA
SecondaryNumber of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories

The participant assessed their overall pain control in the past 24 hours using the PGA 4-point scale where: 0=poor, 1=fair, 2=good and 3=excellent.

Time frame:
Days 5, 8, 15 and 29
Reported as:
Count of participants · Participants
Number of Participants by Patient Global Assessment (PGA) of Pain Control Score Categories
ParticipantsPlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
Day 5 — PGA score 37121
Day 5 — PGA score 24021
Day 5 — PGA score 10001
Day 5 — PGA score 00000
Day 8 — PGA score 37101
Day 8 — PGA score 24020
Day 8 — PGA score 10012
Day 8 — PGA score 00010
Day 15 — PGA score 38121
Day 15 — PGA score 23011
Day 15 — PGA score 10011
Day 15 — PGA score 00000
Day 29 — PGA score 39131
Day 29 — PGA score 22012
Day 29 — PGA score 10000
Day 29 — PGA score 00000
SecondaryNumber of Doses of Rescue Medications Used
Time frame:
Up to 96 hours postsurgery
Reported as:
Mean · doses
Number of Doses of Rescue Medications Used
dosesPlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
Oxycodone9.7 ± 5.925.0 ± NA11.8 ± 5.6811.7 ± 4.93
Opioid14.2 ± 7.408.0 ± NA15.8 ± 6.9016.0 ± 6.08

Adverse events

Collected over Up to 31 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/12 (0%)0/12 (0%)8/12 (66.7%)
Botulinum Neurotoxin Serotype E Dose 10/4 (0%)0/4 (0%)3/4 (75%)
Botulinum Neurotoxin Serotype E Dose 20/4 (0%)0/4 (0%)4/4 (100%)
Botulinum Neurotoxin Serotype E Dose 30/3 (0%)0/3 (0%)3/3 (100%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3
NauseaGastrointestinal disorders6/121/42/42/3
HypoxiaRespiratory, thoracic and mediastinal disorders1/120/40/42/3
ConstipationGastrointestinal disorders2/121/42/40/3
Back painMusculoskeletal and connective tissue disorders1/120/42/40/3
HeadacheNervous system disorders5/121/41/40/3
RashSkin and subcutaneous tissue disorders2/120/40/41/3
VomitingGastrointestinal disorders1/121/41/40/3
DyspepsiaGastrointestinal disorders0/120/41/40/3
PruritusSkin and subcutaneous tissue disorders0/121/41/40/3
Pruritus generalisedSkin and subcutaneous tissue disorders0/121/40/40/3

Baseline characteristics

Safety Population included all participants exposed to any amount of study drug.

Age, Continuous
Age, Continuous(years)PlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3Total
Mean36.5 ± 5.233.0 ± 6.3836.3 ± 7.7241.0 ± 14.036.7 ± 3.29
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3Total
Female1144322
Male10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3Total
Asian00101
Black or African American531211
White or Caucasian612110
Other/Mixed10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBotulinum Neurotoxin Serotype E Dose 1Botulinum Neurotoxin Serotype E Dose 2Botulinum Neurotoxin Serotype E Dose 3Total
Hispanic or Latino612110
Not Hispanic or Latino632213
08

Study locations

2 sites
  • Huntington Ambulatory Surgery Center
    Pasadena, California 91105, United States
  • Lotus Clinical Research, LLC
    Pasadena, California 91105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in Jul 2018, 2 months.

Results were first posted in Aug 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 12, 2018
StartActual
May 8, 2018
Primary completionActual
Jul 10, 2018
CompletionActual
Jul 10, 2018
Results first posted
Aug 5, 2019
Last update
Aug 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03429556
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 12, 2018
Start date
May 8, 2018
Primary completion
Jul 10, 2018
Completion
Jul 10, 2018
Results posted
Aug 5, 2019
Last update
Aug 5, 2019

Study contacts

Joan-En Lin
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type E

Start the discussion